Emergence of invasive pneumococcal disease caused by non-vaccine serotypes in the era of the 7-valent conjugate vaccine;Serotipos no vacunales emergentes causantes de enfermedad neumocócica invasora en la era de la vacuna 7-valente

Anales de Pediatria

Volumn 80, Issue 3, 2014, Pages 173-180

  Gonzalez Martinez F ^a   Navarro Gomez M L ^a   Saavedra Lozano, J ^a   Santos Sebastian M M ^a   Rodriguez Fernandez R ^a   Gonzalez Sanchez M ^a   Cercenado Mansilla, E ^a   Hernandez Sampelayo Matos T ^a  

^a HOSPITAL MATERNO INFANTIL GREGORIO MARAÑÓN   (Spain)

Author keywords

Emerging serotypes; Heptavalent pneumococcal conjugate vaccine; Invasive pneumococcal disease

Indexed keywords

PNEUMOCOCCUS VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE;

ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; CLINICAL FEATURE; HUMAN; IMMUNIZATION; INCIDENCE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MENINGITIS; MICROBIOLOGICAL PARAMETERS; NON VACCINE SEROTYPE; PNEUMOCOCCAL INFECTION; PREVALENCE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SEROTYPE; SPAIN; TERTIARY CARE CENTER; CLASSIFICATION; MICROBIOLOGY; PRESCHOOL CHILD; STREPTOCOCCUS PNEUMONIAE;

CHILD, PRESCHOOL; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEROGROUP; STREPTOCOCCUS PNEUMONIAE;

EID: 84896723845     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2013.05.003     Document Type: Article

References (39)

1. S. Black, H. Shinefield, B. Fireman, E. Lewis, P. Ray, and J.R. Hansen et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group Pediatr Infect Dis J 19 2000 187 195
2. K.L. O'Brien, L.H. Moulton, R. Reid, R. Weatherholtz, J. Oski, and L. Brown et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: Group randomised trial Lancet 362 2003 355 361
3. C. Munoz-Almagro, I. Jordan, A. Gene, C. Latorre, J.J. Garcia-Garcia, and R. Pallares Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine Clin Infect Dis 46 2008 174 182
4. D.J. Isaacman, E.D. McIntosh, and R.R. Reinert Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: Impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines Int J Infect Dis 14 2010 e197 e209
5. J. Picazo, J. Ruiz-Contreras, J. Casado-Flores, E. Giangaspro, F. Del Castillo, and T. Hernández-Sampelayo et al. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar Clin Vaccine Immunol 18 2011 89 94
6. J.J. Picazo Management of antibiotic-resistant Streptococcus pneumoniae infections and the use of pneumococcal conjugate vaccines Clin Microbiol Infect 15 Suppl 3 2009 4 6
7. J.P. Lynch 3rd, and G.G. Zhanel Streptococcus pneumoniae: Epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines Curr Opin Pulm Med 16 2010 217 225
8. T. Vesikari, J. Wysocki, B. Chevallier, A. Karvonen, H. Czaika, and J.P. Arsène et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7 vCRM vaccine Pediatr Infect Dis J 28 4 Suppl 2009 S66 S76
9. D.M. Kieninger, K. Kueper, K. Steul, C. Juergens, N. Ahlers, and S. Baker et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany Vaccine 28 2010 4192 4203
10. T. Pilishvili, C. Lexau, M.M. Farley, J. Hadler, L.H. Harrison, and N.M. Bennett et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine J Infect Dis 201 2010 32 41
11. A. Barricarte, A. Gil-Setas, L. Torroba, J. Castilla, A. Petit, and I. Polo et al. Invasive pneumococcal disease in children younger than 5 years in Navarra, Spain (2000-2005). Impact of the conjugate vaccine Med Clin (Barc) 129 2007 41 45
12. I. Obando, L.A. Arroyo, D. Sanchez-Tatay, D. Tarragó, D. Moreno, and W.P. Hausdorff et al. Molecular epidemiology of paediatric invasive pneumococcal disease in southern Spain after the introduction of heptavalent pneumococcal conjugate vaccine Clin Microbiol Infect 13 2007 347 348
13. L. Salleras, A. Domínguez, P. Ciruela, C. Izquierdo, E. Navas, and N. Torner et al. Changes in serotypes causing invasive pneumococcal disease (2005-2007 vs. 1997-1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine Clin Microbiol Infect 15 2009 997 1001
14. J. Benito-Fernandez, S.M. Raso, I. Pocheville-Gurutzeta, J. Sanchez Etxaniz, B. Azcunaga-Santibanez, and S. Capape-Zache Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque Country of Spain Pediatr Infect Dis J 26 2007 667 671
15. J. Aristegui, E. Bernaola, I. Pocheville, C. García, L. Arranz, and G. Durán et al. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine Eur J Clin Microbiol Infect Dis 26 2007 303 310
16. A. Lepoutre, E. Varon, S. Georges, L. Gutmann, and D. Levy-Bruhl Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006 Euro Surveill 13 2008 1 6
17. R.J. Singleton, T.W. Hennessy, L.R. Bulkow, L.L. Hammitt, T. Zulz, and D.A. Hurlburt et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage JAMA 297 2007 1784 1792
18. S.L. Kaplan, E.O. Mason Jr., E.R. Wald, G.E. Schutze, J.S. Bradley, and T.Q. Tan et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine Pediatrics 113 3 Pt 1 2004 443 449
19. G.E. Schutze, N.C. Tucker, and E.O. Mason Jr. Impact of the conjugate pneumococcal vaccine in arkansas Pediatr Infect Dis J 23 2004 1125 1129
20. D.J. Farrell, K.P. Klugman, and M. Pichichero Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States Pediatr Infect Dis J 26 2007 123 128
21. L.A. Hicks, L.H. Harrison, B. Flannery, J.L. Hadler, W. Schaffner, and A.S. Craig et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004 J Infect Dis 196 2007 1346 1354
22. K. Hsu, S. Pelton, S. Karumuri, D. Heisey-Grove, and J. Klein Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine Pediatr Infect Dis J 24 2005 17 23
23. A.P. Steenhoff, S.S. Shah, A.J. Ratner, S.M. Patil, and K.L. McGowan Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia Clin Infect Dis 42 2006 907 914
24. B.E. Gonzalez, K.G. Hulten, L. Lamberth, S.L. Kaplan, and E.O. Mason Jr. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine Pediatr Infect Dis J 25 2006 301 305
25. C. Feldman, and R. Anderson New insights into pneumococcal disease Respirology 14 2009 167 179
26. C. Ardanuy, F. Tubau, R. Pallares, L. Calatayud, M.A. Domínguez, and D. Rolo et al. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007 Clin Infect Dis 48 2009 57 64
27. I. Obando, L.A. Arroyo, D. Sanchez-Tatay, D. Moreno, W.P. Hausdorff, and A.B. Brueggemann Molecular typing of pneumococci causing parapneumonic empyema in Spanish children using multilocus sequence typing directly on pleural fluid samples Pediatr Infect Dis J 25 2006 962 963
28. C.G. Grijalva, J.P. Nuorti, Y. Zhu, and M.R. Griffin Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States Clin Infect Dis 50 2010 805 813
29. J.M. Bender, K. Ampofo, K. Korgenski, J. Daly, A.T. Pavia, and E.O. Mason et al. Pneumococcal necrotizing pneumonia in Utah: Does serotype matter? Clin Infect Dis 46 2008 1346 1352
30. E.M. Mokaddas, V.O. Rotimi, and M.J. Albert Implications of Streptococcus pneumoniae penicillin resistance and serotype distribution in Kuwait for disease treatment and prevention Clin Vaccine Immunol 15 2008 203 207
31. W.P. Hausdorff The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease Vaccine 25 2007 2406 2412
32. S.L. Kaplan, W.J. Barson, P.L. Lin, S.H. Stovall, J.S. Bradley, and T.Q. Tan et al. Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children Pediatrics 125 2010 429 436
33. K.M. Mothibeli, M. du Plessis, A. von Gottberg, L. de Gouveia, P. Adrian, and S.A. Madhi et al. An unusual pneumococcal sequence type is the predominant cause of serotype 3 invasive disease in South Africa J Clin Microbiol. 48 2010 184 191
34. M. Guevara, A. Barricarte, A. Gil-Setas, J.J. García-Irure, X. Beristain, and L. Torroba et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain Clin Microbiol Infect 15 2009 1013 1019
35. R. Dias, and M. Canica Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine FEMS Immunol Med Microbiol 51 2007 35 42
36. C.A. Ihekweazu, D.A. Dance, R. Pebody, R.C. George, M.D. Smith, and P. Waight et al. Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: South West England, 1996-2005 Epidemiol Infect 136 2008 1096 1102
37. M.R. Jacobs, C.E. Good, S. Bajaksouzian, and A.R. Windau Emergence of Streptococcus pneumoniae serotypes 19A, 6 C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine Clin Infect Dis 47 2008 1388 1395
38. C.G. Whitney, T. Pilishvili, M.M. Farley, W. Schaffner, A.S. Craig, and R. Lynfield et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study Lancet 368 2006 1495 1502
39. G. Carvalho Mda, F.C. Pimenta, R.E Gertz Jr., H.H. Joshi, A.A. Trujillo, and L.E. Keys et al. PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6 C, in the United States in 1999 and 2006 to 2007 J Clin Microbiol 47 2009 554 559